Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Website: catalystpharma.com



Growth: Good revenue growth rate 82.0%, there is acceleration compared to average historical growth rates 53.6%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +22.1%. On average the margin is decreasing unsteadily. Gross margin is high, +77.5%. In the last quarter the company beat the estimated EPS, +28.1%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -10.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 234.0% higher than minimum and 28.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 5.7x by EV / Sales multiple , the company can be 54.7% undervalued

Insiders: For the last 3 months insiders sold company shares on $0.4 mln (-0.024% of cap.)

Key Financials (Download financials)

Ticker: CPRX
Share price, USD:  (-1.4%)15.13
year average price 14.01  


year start price 16.48 2023-04-22

max close price 17.51 2023-05-10

min close price 11.50 2023-05-26

current price 15.13 2024-04-20
Common stocks: 106 279 736

Dividend Yield:  0.0%
FCF Yield LTM: -10.5%
EV / LTM EBITDA: 16.8x
EV / EBITDA annualized: 8.8x
Last revenue growth (y/y):  82.0%
Last growth of EBITDA (y/y):  35.5%
Historical revenue growth:  53.6%
Historical growth of EBITDA:  43.0%
EV / Sales: 3.7x
Margin (EBITDA LTM / Revenue): 22.1%
Fundamental value created in LTM:
Market Cap ($m): 1 608
Net Debt ($m): -126
EV (Enterprise Value): 1 482
Price to Book: 4.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-29Zacks Investment Research

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

2024-03-05GlobeNewsWire

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

2024-02-29Zacks Investment Research

Catalyst (CPRX) Q4 Earnings & Sales Beat Estimates, Stock Up

2024-02-28Zacks Investment Research

Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates

2024-02-27GlobeNewsWire

Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

2024-02-14GlobeNewsWire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

2024-01-18InvestorPlace

Next Big Thing: 3  Biotech Stocks to Watch for Groundbreaking Advances

2024-01-15The Motley Fool

3 Biotech Stocks You Can Buy and Hold for the Next Decade

2024-01-10Zacks Investment Research

5 Value Stocks With Strong Earnings Yield to Rev Up Returns

2024-01-03Zacks Investment Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CPRX CPRX CPRX CPRX CPRX CPRX
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-28 2023-11-08 2023-08-09 2023-05-10 2023-03-15 2022-11-09
acceptedDate 2024-02-28 17:16:26 2023-11-08 16:06:08 2023-08-09 16:07:07 2023-05-10 16:07:06 2023-03-15 16:06:26 2022-11-09 16:07:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 111M 103M 100M 85M 61M 57M
costOfRevenue 25M 14M 12M 10M 11M 10M
grossProfit 86M 89M 88M 75M 50M 48M
grossProfitRatio 0.775 0.862 0.879 0.883 0.816 0.831
researchAndDevelopmentExpenses 2M 84M 4M 4M 4M 8M
generalAndAdministrativeExpenses 13M 12M 10M 12M 7M 7M
sellingAndMarketingExpenses 29M 22M 18M 18M 8M 8M
sellingGeneralAndAdministrativeExpenses 42M 34M 28M 30M 15M 14M
otherExpenses 5M -833 000 2M 7M 2M 0
operatingExpenses 44M 126M 41M 40M 19M 22M
costAndExpenses 69M 140M 53M 50M 30M 32M
interestIncome -4M 0 2M 0 0 0
interestExpense 2M 0 0 -2M -3M -905 000
depreciationAndAmortization 9M 9M 9M 7M 615 000 553 000
ebitda 51M -29M 55M 42M 31M 26M
ebitdaratio 0.460 -0.279 0.555 0.494 0.507 0.448
operatingIncome 42M -37M 47M 36M 31M 25M
operatingIncomeRatio 0.377 -0.362 0.469 0.417 0.507 0.439
totalOtherIncomeExpensesNet 5M -833 000 2M 2M 2M 905 000
incomeBeforeTax 47M -38M 49M 37M 33M 26M
incomeBeforeTaxRatio 0.422 -0.370 0.487 0.437 0.543 0.454
incomeTaxExpense 12M -7M 11M 8M 8M 3M
netIncome 35M -31M 38M 30M 25M 23M
netIncomeRatio 0.315 -0.300 0.379 0.346 0.419 0.397
eps 0.330 -0.290 0.360 0.280 0.240 0.220
epsdiluted 0.310 -0.290 0.330 0.260 0.220 0.200
weightedAverageShsOut 107M 107M 114M 106M 105M 103M
weightedAverageShsOutDil 114M 107M 114M 114M 114M 112M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CPRX CPRX CPRX CPRX CPRX CPRX
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-28 2023-11-08 2023-08-09 2023-05-10 2023-03-15 2022-11-09
acceptedDate 2024-02-28 17:16:26 2023-11-08 16:06:08 2023-08-09 16:07:07 2023-05-10 16:07:06 2023-03-15 16:06:26 2022-11-09 16:07:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 138M 121M 179M 148M 298M 256M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 138M 121M 179M 148M 298M 256M
netReceivables 54M 48M 43M 33M 10M 10M
inventory 16M 9M 11M 10M 7M 7M
otherCurrentAssets 13M 352 000 361 000 7M 5M 466 000
totalCurrentAssets 219M 192M 241M 199M 321M 276M
propertyPlantEquipmentNet 4M 4M 4M 4M 4M 4M
goodwill 0 0 0 0 0 0
intangibleAssets 194M 167M 176M 184M 32M 33M
goodwillAndIntangibleAssets 194M 167M 176M 184M 32M 33M
longTermInvestments 16M 13M 179M 0 0 0
taxAssets 38M 37M 23M 20M 19M 20M
otherNonCurrentAssets -1.000 0 -179M 0 9000.000 9000.000
totalNonCurrentAssets 253M 221M 203M 208M 55M 57M
otherAssets 1.000 0 0 0 0 0
totalAssets 472M 413M 444M 407M 376M 333M
accountPayables 15M 5M 4M 3M 4M 3M
shortTermDebt 369 000 361 000 353 000 345 000 337 000 330 000
taxPayables 729 000 912 000 5M 18M 9M 4M
deferredRevenue 729 000 52M 47M 0 0 0
otherCurrentLiabilities 60M 374 000 455 000 53M 53M 42M
totalCurrentLiabilities 76M 58M 53M 57M 58M 45M
longTermDebt 3M 3M 3M 3M 4M 4M
deferredRevenueNonCurrent -1.000 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 2M 0 0 0 0 0
otherNonCurrentLiabilities 3M 4M 13M 13M 14M 16M
totalNonCurrentLiabilities 8M 7M 16M 17M 18M 18M
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 3M 4M 4M 3M 4M 4M
totalLiabilities 84M 65M 69M 74M 75M 63M
preferredStock 0 0 0 0 0 0
commonStock 107 000 107 000 107 000 106 000 105 000 104 000
retainedEarnings 121M 86M 117M 79M 50M 24M
accumulatedOtherComprehensiveIncomeLoss 14 000 15 000 19 000 11 000 24 000 32 000
othertotalStockholdersEquity 266M 262M 258M 254M 250M 246M
totalStockholdersEquity 388M 349M 375M 334M 300M 270M
totalEquity 388M 349M 375M 334M 300M 270M
totalLiabilitiesAndStockholdersEquity 472M 413M 444M 407M 376M 333M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 472M 413M 444M 407M 376M 333M
totalInvestments 16M 13M 179M 0 0 0
totalDebt 4M 4M 4M 3M 4M 4M
netDebt -134M -117M -175M -145M -295M -252M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CPRX CPRX CPRX CPRX CPRX CPRX
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-28 2023-11-08 2023-08-09 2023-05-10 2023-03-15 2022-11-09
acceptedDate 2024-02-28 17:16:26 2023-11-08 16:06:08 2023-08-09 16:07:07 2023-05-10 16:07:06 2023-03-15 16:06:26 2022-11-09 16:07:39
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 35M -31M 38M 30M 25M 23M
depreciationAndAmortization 9M 9M 9M 7M 615 000 553 000
deferredIncomeTax 883 000 -14M -3M -2M 1M 934 000
stockBasedCompensation 4M 4M 3M 3M 2M 2M
changeInWorkingCapital 8M -4M -16M -26M 11M 11M
accountsReceivables -5M -5M -9M -23M -1M 250 000
inventory -7M 2M -423 000 577 000 327 000 718 000
accountsPayables 10M 177 000 1M -584 000 1M 214 000
otherWorkingCapital 10M -251 000 -7M 23M 10M 10M
otherNonCashItems -1M 81M 65 000 194 000 63 000 4M
netCashProvidedByOperatingActivities 56M 45M 31M 12M 40M 41M
investmentsInPropertyPlantAndEquipment -36M -79M 0 -74 000 -992 000 -29 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 -13M 0 0 -10M 0
salesMaturitiesOfInvestments 0 0 0 0 -19M 10M
otherInvestingActivites -2M 0 0 -162M 659 000 -10M
netCashUsedForInvestingActivites -38M -93M 0 -162M -30M -132 000
debtRepayment 0 0 0 0 0 0
commonStockIssued 693 000 212 000 617 000 1M 4M 0
commonStockRepurchased 529 000 0 -52 000 0 2M -7M
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -2M -10M -779 000 -1M -4M 11M
netCashUsedProvidedByFinancingActivities -665 000 -10M -214 000 149 000 2M 4M
effectOfForexChangesOnCash -61M 61M 0 0 30M 0
netChangeInCash 17M -58M 31M -150M 42M 45M
cashAtEndOfPeriod 138M 121M 179M 148M 298M 256M
cashAtBeginningOfPeriod 121M 179M 148M 298M 256M 211M
operatingCashFlow 56M 45M 31M 12M 40M 41M
capitalExpenditure -36M -79M 0 -74 000 -992 000 -29 000
freeCashFlow 20M -34M 31M 12M 39M 41M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-29 ET (fiscal 2023 q4)
2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-16 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-28 23:03 ET
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-27 13:03 ET
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
2024-02-21 14:00 ET
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology
2024-02-14 13:03 ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2024-01-09 21:05 ET
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering
2024-01-05 13:02 ET
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
2024-01-04 21:49 ET
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2023-12-18 11:30 ET
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
2023-12-05 13:03 ET
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
2023-12-04 13:03 ET
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
2023-11-16 13:05 ET
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
2023-11-08 21:11 ET
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
2023-11-02 14:37 ET
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
2023-10-30 12:03 ET
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
2023-10-26 19:19 ET
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals
2023-10-23 12:03 ET
Catalyst Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 8, 2023
2023-10-19 12:03 ET
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
2023-10-16 12:03 ET
Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida
2023-10-13 12:03 ET
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE®
2023-09-18 12:03 ET
Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference
2023-08-16 14:56 ET
Catalyst Pharmaceuticals Announces Abstract on Lambert Eaton Myasthenic Syndrome (LEMS) to be Presented at the Upcoming IASLC 2023 World Conference of Lung Cancer
2023-08-14 12:05 ET
Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress
2023-08-09 20:17 ET
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-25 12:03 ET
Patrick J. McEnany Announces Intention to Retire as CEO of Catalyst Pharmaceuticals by Year-End
2023-07-24 12:03 ET
Catalyst Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 9, 2023
2023-07-19 10:00 ET
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
2023-06-20 10:00 ET
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
2023-06-01 12:03 ET
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
2023-05-30 12:03 ET
Catalyst Pharmaceuticals Appoints Tamar Thompson to its Board of Directors
2023-05-10 20:27 ET
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
2023-05-09 12:03 ET
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
2023-05-01 12:03 ET
Catalyst Pharmaceuticals Announces Release of Inaugural ESG Report
2023-04-24 12:03 ET
Catalyst Pharmaceuticals to Report First Quarter 2023 Financial Results on May 10, 2023
2023-04-20 12:03 ET
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
2023-03-15 20:11 ET
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-03-08 16:20 ET
Catalyst Pharmaceuticals Announces a Recent Third-Party Publication in Peer-Reviewed Journal Epilepsia Showing Perampanel (FYCOMPA®) Demonstrated High Efficacy in Patients with Rare Genetic Epilepsies
2023-03-01 13:03 ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 15, 2023
2023-02-22 13:03 ET
Catalyst Pharmaceuticals to Ring the Nasdaq Closing Bell in Honor of International Rare Disease Day
2023-02-07 13:03 ET
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 Total Revenues and Provides Full Year 2023 Revenue Guidance
2023-01-25 13:03 ET
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
2023-01-23 18:25 ET
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
2023-01-23 13:03 ET
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
2022-12-19 21:10 ET
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
2022-11-09 21:11 ET
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
2022-11-07 13:03 ET
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
2022-10-25 12:03 ET
Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
2022-09-29 15:18 ET
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for FIRDAPSE® Expanding Patient Population to Include Pediatric Patients
2022-09-12 23:30 ET
Catalyst Pharmaceuticals Set to Join S&P SmallCap 600
2022-09-09 12:03 ET
Catalyst Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-24 12:03 ET
Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference
2022-08-09 20:25 ET
Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update
2022-07-26 12:03 ET
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
2022-07-12 10:00 ET
Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical
2022-05-17 12:03 ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2022-05-10 20:11 ET
Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update
2022-04-25 12:03 ET
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
2022-03-16 20:20 ET
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2022-03-11 13:03 ET
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®
2022-03-08 13:03 ET
Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies
2022-03-03 14:20 ET
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022
2022-03-02 13:03 ET
Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio
2022-02-24 13:03 ET
Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022
2022-02-17 13:03 ET
Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022
2022-02-07 13:03 ET
Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update
2022-02-03 13:03 ET
Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
2022-01-28 18:46 ET
Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst
2022-01-10 13:03 ET
Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
2022-01-04 12:30 ET
Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences
2021-12-06 12:00 ET
Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan
2021-11-15 21:15 ET
Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
2021-11-09 21:14 ET
Catalyst Pharmaceuticals Reports Third Quarter 2021 Financial Results
2021-10-25 12:03 ET
Catalyst Pharmaceuticals to Report Third Quarter 2021 Financial Results on November 9, 2021
2021-09-30 16:08 ET
Catalyst Pharmaceuticals Receives Positive Decision from Appeals Court That Supports Orphan Drug Exclusivity for Firdapse® for LEMS
2021-09-17 12:03 ET
Catalyst Pharmaceuticals to Participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
2021-09-10 12:03 ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2021-08-16 12:03 ET
Catalyst Pharmaceuticals Appoints Mary Coleman as Vice President, Head of Investor Relations
2021-08-09 20:39 ET
Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
2021-07-26 12:03 ET
Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021
2021-07-19 12:03 ET
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®
2021-07-06 12:03 ET
Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer
2021-06-29 12:03 ET
Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors
2021-06-28 20:30 ET
Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®
2021-06-28 12:03 ET
Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan
2021-06-03 17:20 ET
Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®
2021-05-19 12:03 ET
Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2021-05-10 21:29 ET
Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update
2021-05-03 12:05 ET
Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021
2021-03-22 12:03 ET
Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program
2021-03-15 21:26 ET
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update
2021-03-04 16:00 ET
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021
2021-02-22 13:03 ET
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
2021-01-06 13:07 ET
Catalyst Pharmaceuticals Announces Strategic Plan for Product Portfolio Expansion for Long-Term Success and Provides Corporate Update
2020-11-09 22:20 ET
Catalyst Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update
2020-11-02 13:03 ET
Catalyst Pharmaceuticals to Hold Third Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, November 10th, 2020
2020-10-19 10:03 ET
Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx
2020-10-06 15:15 ET
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
2020-09-29 20:40 ET
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
2020-08-26 13:40 ET
KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity
2020-08-18 12:03 ET
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
2020-08-11 10:00 ET
Catalyst Pharmaceuticals Announces Notice of Allowance of a U.S. Patent Application for "Methods of Administering 3,4-Diaminopyridine"
2020-08-10 20:15 ET
Catalyst Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update
2020-08-06 12:03 ET
Catalyst Pharmaceuticals’ Firdapse® (amifampridine phosphate) Receives Marketing Approval in Canada for Patients with LEMS
2020-08-03 20:15 ET
Catalyst Pharmaceuticals Announces Change to a Virtual Meeting Format for the 2020 Annual Meeting of Stockholders
2020-08-03 12:03 ET
Catalyst Pharmaceuticals to Hold Second Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 11th, 2020
2020-07-31 15:10 ET
Catalyst Pharmaceuticals Comments on Magistrate Judge's Report and Recommendation in its Lawsuit against the FDA
2020-06-23 12:03 ET
Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
2020-06-01 12:03 ET
Catalyst Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
2020-05-11 20:17 ET
Catalyst Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-04 12:03 ET
Catalyst Pharmaceuticals to Hold First Quarter 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 12th, 2020
2020-04-08 10:00 ET
Catalyst Pharmaceuticals Provides Update on Impact of COVID-19 Pandemic on its Business Activities
2020-03-16 21:26 ET
Catalyst Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update
2020-03-10 12:03 ET
Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 17th, 2020
2020-02-27 13:03 ET
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2020
2020-02-26 13:03 ET
Catalyst Pharmaceuticals to Present at the Cowen 40th Annual Health Care Conference
2020-02-06 13:03 ET
Catalyst Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference
2020-02-04 13:02 ET
Catalyst Pharmaceuticals Appoints David Ailinger as Vice President, Business Development
2020-01-06 13:03 ET
Catalyst Pharmaceuticals Pre-Announces Estimated Firdapse® Revenues and Provides Updates on Advancement of Clinical Development Programs
2019-11-26 13:03 ET
Catalyst Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference
2019-11-12 21:39 ET
Catalyst Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-10-31 12:03 ET
Catalyst Pharmaceuticals to Hold Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, November 13th, 2019
2019-10-30 10:03 ET
Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
2019-09-25 12:02 ET
Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
2019-09-23 18:55 ET
Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources
2019-09-13 10:03 ET
Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
2019-09-11 20:19 ET
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
2019-03-11 08:03 ET
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019
2019-02-28 13:03 ET
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
2019-02-26 13:03 ET
Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome

SEC forms

Show financial reports only

SEC form 10
2024-02-28 17:16 ET
Catalyst Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 16:06 ET
Catalyst Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q3
SEC form 6
2023-08-09 16:34 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 10
2023-08-09 16:07 ET
Catalyst Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-28 16:30 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-21 16:30 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-12 16:31 ET
Catalyst Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-23 16:31 ET
Catalyst Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Catalyst Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-10 16:30 ET
Catalyst Pharmaceuticals published news for 2023 q1
SEC form 6
2023-03-31 16:45 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-03-15 16:41 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-15 16:06 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 10
2023-03-15 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-07 16:40 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-07 08:19 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-30 16:15 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-24 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2023-01-23 08:25 ET
Catalyst Pharmaceuticals published news for 2022 q4
SEC form 6
2022-12-22 16:31 ET
Catalyst Pharmaceuticals published news for 2022 q3
SEC form 6
2022-11-09 16:32 ET
Catalyst Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 16:07 ET
Catalyst Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q3
SEC form 6
2022-09-29 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-09-19 17:28 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-09-09 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-09 17:11 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 16:09 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-05 16:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-07-12 08:30 ET
Catalyst Pharmaceuticals published news for 2022 q2
SEC form 6
2022-05-10 16:31 ET
Catalyst Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-10 16:07 ET
Catalyst Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Catalyst Pharmaceuticals reported for 2022 q1
SEC form 6
2022-04-29 16:32 ET
Catalyst Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-16 16:53 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-16 16:06 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-16 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-11 16:15 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-02 17:00 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-07 16:49 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-03 16:55 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-28 17:17 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-10 16:17 ET
Catalyst Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-06 16:30 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-12-03 17:28 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-12 16:31 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-09 17:29 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 16:07 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-26 16:46 ET
Catalyst Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-30 17:13 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-16 16:13 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-09 17:28 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 16:34 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-19 16:21 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-06 08:15 ET
Catalyst Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-30 16:30 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-29 08:22 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-28 17:02 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-03 17:06 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-10 17:43 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 17:23 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 16:31 ET
Catalyst Pharmaceuticals published news for 2021 q1
SEC form 6
2021-03-22 08:35 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-16 08:11 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 10
2021-03-15 17:17 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 16:28 ET
Catalyst Pharmaceuticals published news for 2020 q4
SEC form 6
2020-11-09 17:46 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-09 17:09 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-19 08:04 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-06 17:26 ET
Catalyst Pharmaceuticals published news for 2020 q3
SEC form 6
2020-09-29 19:38 ET
Catalyst Pharmaceuticals published news for 2020 q2